Clinical trials: Cancer Refractory
Follicular Lymphoma
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
The purpose of this study is to determine what dose of bortezomib in combination with tositumomab I-131 is tolerable whether bortezomib and Tositumomab I-131 are effective in the treatment of relapsed or refractory non-hodgkin's…
- Trial name
- NCT00479167
- Testing
- Bortezomib and Tositumomab I-131
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rush University Medical Center
Refractory Solid Tumors in Children
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin
This phase I study is designed to determine the maximum tolerated dose of Irinotecan given intravenous for 5 days every 3 weeks in combination with fixed doses of Vincristine, Temozolomide and Bevacizumab (VIT-B) in patients with…
- Trial name
- VIT-B (NCT00993044)
- Testing
- Irinotecan, Vincristine, Temozolomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Los Angeles
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well ixazomib citrate, pomalidomide, dexamethasone, and stem cell transplantation works in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Trial name
- NCT03202628
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Neuroblastoma
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
Primary: Evaluate safety, feasibility, persistence, and anti-tumor effect of infused haploidentical donor-derived natural killer (NK) cells and low-dose interleukin-2 (IL-2).
- Trial name
- NCT00698009
- Testing
- Fludarabine, Cyclophosphamide, Natural Killer Cell Infusion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer Metastatic
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
The primary goal of this study is to characterize the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012.
- Trial name
- NCT03531632
- Testing
- MGD007 + MGA012
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- MacroGenics
Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
This phase II trial is studying how well saracatinib works in treating patients with relapsed or refractory thymoma or thymic cancer.
- Conditions
- Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma, Stage IVA Thymoma
- Trial name
- NCT00718809
- Testing
- saracatinib
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
The purpose of this study is to assess overall response rate [ORR, including complete response (CR) and partial response (PR)], of daratumumab in participants with non-Hodgkin's lymphoma [a cancer of the lymph nodes (or…
- Conditions
- Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- NCT02413489
- Testing
- Daratumumab
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
Adult Medulloblastoma
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma.
- Trial name
- NCT00939484
- Testing
- Pharmacological Study, Vismodegib
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
This study evaluates camidanlumab tesirine in participants with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma.
- Trial name
- NCT02432235
- Testing
- Camidanlumab tesirine
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 133 people
- Sponsor
- ADC Therapeutics S.A.
Hormone Refractory Prostate Cancer
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory)…
- Trial name
- NCT00928252
- Testing
- IV fluorine-18 labeled methylcholine before PET/CT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Queen's Medical Center
Pheochromocytoma, Paraganglioma
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
This clinical trial is designed to evaluate the effectiveness and collect additional safety information on AZEDRA® (iobenguane I 131) for the treatment of metastatic or relapsed/refractory (to other treatment) or unresectable…
- Trial name
- NCT00874614
- Testing
- Ultratrace® Iobenguane I131
- Where
- 10 sites in United States
- Volunteers
- 74 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Multiple Myeloma
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens [progression free survival (PFS)].
- Trial name
- NCT01478048
- Testing
- Elotuzumab, Bortezomib, Dexamethasone
- Where
- 77 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Multiple Myeloma
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.
- Trial name
- NCT02079519
- Testing
- Bevacizumab
- Where
- 4 sites in Austria
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles.
- Trial name
- NCT00056160
- Testing
- CC-5013, Dexamethasone
- Where
- 49 sites in United States, Canada
- Volunteers
- 353 people
- Sponsor
- Celgene
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
- Trial name
- NCT04052997
- Testing
- Camidanlumab Tesirine
- Where
- 73 sites in United States, Belgium and 9 more
- Volunteers
- 117 people
- Sponsor
- ADC Therapeutics S.A.
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor or Lymphoma
An Open Label Dose Escalation Study Of E7080
The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.
- Trial name
- NCT00121719
- Testing
- Lenvatinib
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.